Electric air taxis are on the way – quiet eVTOLs may be flying passengers as early as 2025 
Adidas Strategizes to Sustain Sneaker Sales Surge as Samba, Gazelle Drive Growth 
Anthropic Launches Claude AI App on iPhone to Rival OpenAI’s ChatGPT 
KFC Japan Celebrates Children’s Day with Samurai Colonel Tradition 
Jordan Brand Wings Unveils Air Jordan I Mid Subway, Celebrating NYC's MTA Crews 
Taylor Swift, Justin Bieber, Billie Eilish Universal Music Label Signs New Deal With TikTok, Ending Dispute 
Monster Beverage Sees Robust Growth with an 11.8% Revenue Surge 
Comcast Drops Bally Sports Channels, Stops Broadcast of MLB Team Games 
2025 Sees SK hynix's HBM Chips Fully Booked Amidst AI Surge 
Coca-Cola Europacific Partners’ Finance Chief Resigns, Moves to Johnnie Walker’s Diageo Company 
Biden Administration Set to Finalize Stricter EV Tax Credit Rules 
Kakao Enhances AI Focus, Merges Kakao Brain Into Core Operations 
Tesla Drivers Get $4k Off 2024 Chevy Blazer EV; Costco Auto Slashes Prices on New EVs 
Peloton CEO Quits, Company Slashes 15% of Its Workforce as Restructuring Begins 
Major Victory for Bayer's Monsanto as Appeals Court Overturns $185 Million Award in Chemical Exposure Case 
Tesla Granted South Korean Emission Credit Trading Rights by Environmental Ministry 
Kakao Gets Approval to Acquire SM Entertainment Controlling Stake 
NEW YORK, Feb. 09, 2017 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at the annual BIO CEO & Investor Conference in New York from February 13-14, 2017 at the Waldorf Astoria Hotel in New York City.
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
AXIM Biotech’s presentation will be available for download on Monday, February 13th at this link as well as previous presentations.
About AXIM
AXIM Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, please visit www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media [email protected] P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling [email protected] P. +1646 824-2857 Lucia Domville, Grayling [email protected] P. +1646 284-9416 Corporate Contact Info North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
